Oncimmune Holdings plc Distributors signed in Korea and Israel – Zeus Capital Comments

Oncimmune Holdings plc (LON:ONC) is a pioneering UK-based biotechnology company which has developed a blood test for the early cancer detection of lung cancer (using its EarlyCDT® platform which measures auto-antibodies against specific panels of tumour-associated antigens). This morning the company announced that it has signed two new exclusive distribution agreements in Korea and Israel with Dow Biomedica/Biodiscovery (DBB) and Best Medical Opinion (BMO), respectively. These companies are both leading independent distributors in their countries and have committed to long-term contracts of 4 (DBB) and 5 (BMO) years, both commencing on May 1st, 2017. As the first distributors of Oncimmune’s innovative new EarlyCDT®-Lung diagnostic tests in these markets, we are encouraged that both companies have agreed to minimum sales levels from year 2 which cumulatively total £5.2 million over the combined 4 and 5 year contracts. We expect these base case sales will generate gross margins of over 80%.

South Korea with its population of just over 50 million people and Israel with almost 8.5 million, represent potentially good sized market opportunities for an early lung cancer detection test with roughly 20% of the adult population being smokers. In Israel it is estimated that there are some 8,000 smoking-related deaths annually with direct medical costs of approximately $1 billion.

DBB currently acts as the distributor for a number of well-known diagnostics companies including Abbott and Illumina. It currently sells a variety of tests in oncology such as Her2 (for Herceptin use in breast cancer patients) and ALK (for Xalkori, Zykadia, or Alecensa use in non-small cell lung cancer patients).

Both DBB and BMO were chosen for their closeness to clinician prescribers, given the high importance of educating these customers about the advantages of early lung cancer detection and the excellent performance of EarlyCDT®-Lung. The long-term nature of the initial contracts underscores the commitments of these companies to invest time and effort in education and marketing the tests.

In both countries we believe the test will be initially available for a short time in its current form as a central laboratory test with blood samples being analysed in Oncimmune’s Kansas lab. However, the EarlyCDT®-Lung Kits which are in the stages of validation for CE Marking are expected to be ready in the near future. In Israel we expect that once the CE Mark has been obtained, the Kit will be available commercially with only minor importation/registration required. In Korea, the Ministry of Food and Drug Safety has oversight of product registrations and it is thought that the registration process will take approximately 8 months and be supported by DBB who will be the importer and registration license holder for the test. Commercial sales are expected to begin around the end of the year or start of next year.

Comment: Today’s news represents the first of what we expect will be many distribution agreements for countries in regions from Asia to Europe and elsewhere. A condition of entering many of these markets is the availability of a test Kit which simplifies the running of the test for all users and makes it appropriate for the vast majority of hospital and small decentralised laboratories where the only equipment required is a standard, inexpensive 96-well ELISA plate reader (already present in most labs). The final validation for the CE Mark for the EarlyCDT®-Lung Kit will be a significant achievement for the company and we believe will trigger the signing of many new distributors, particularly in Asian markets where there is a strong preference for Kit-based tests.

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    Oncimmune Holdings PLC

    More articles like this

    Oncimmune Holdings report two further ImmunoINSIGHTS contracts signed

    Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, today announced the signing of two new ImmunoINSIGHTS commercial contracts. The first contract is with an US-based clinical-stage biopharmaceutical company which is developing first-in-class cellular immunotherapies for cancer

    Oncimmune signs new commercial follow-on contract 

    Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has announced the signing of a new commercial follow-on contract with a world-leading medical research organisation based in the US, to validate the findings from a previous

    Oncimmune signs go-to-market partnership with Synexa Life Sciences

    Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has announced the signing of a go-to-market partnership with Synexa Life Sciences BV, a global leader in biomarker and bioanalytical science, focused on delivering a range of biomarker

    Oncimmune signs new commercial contract with Verily Life Sciences 

    Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has announced the signing of a new commercial contract with Verily Life Sciences LLC, an Alphabet company (parent company to Google), focusing on the autoantibody profiling of patients

    Oncimmune Holdings Notice of half year results

    Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has stated today that it will be announcing its half year results for the six months ended 30 November 2021 on 28 February 2022. ImmunoINSIGHTS Service Business Oncimmune

    Oncimmune achieves FY2021 revenue of £3.7 million

    Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has announced its audited results for the year ended 31 May 2021 and provides an update on recent progress and the outlook for the current financial year.

    Oncimmune to evaluate the profile of patients using ImmunoINSIGHTS

    Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has announced it has signed an autoantibody profiling agreement with a leading global pharmaceutical company to evaluate the autoantibody profiles of patient samples in various autoimmune diseases. The